Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Following revisions to Statistics Korea’s Korean Standard Industrial Classification (KSIC) and KRX KOSPI market regulations, Celltrion’s sub-industry classification will be changed from “Manufacture of basic pharmaceutical products and biological preparations” to “Manufacture of basic pharmaceutical products” effective July 1, 2024.
📊 [Key Disclosure Details & Financial Highlights]
- Overview
- Company Name: Celltrion, Inc.
- Effective Date: July 01, 2024
- Regulatory/Issuing Body: Korea Exchange (KRX)
- Industry Classification Changes
- Previous Classification (Code):
- Section (Macro): Manufacturing (03)
- Division (Medium): Manufacture of medical substances and pharmaceuticals (21)
- Group (Sub-class): Manufacture of basic pharmaceutical products and biological preparations (01)
- Revised Classification (Code):
- Section (Macro): Manufacturing (03)
- Division (Medium): Manufacture of medical substances and pharmaceuticals (21)
- Group (Sub-class): Manufacture of basic pharmaceutical products (01)
- Reason & Regulatory Basis
- Reason for Change: Revisions to the Korean Standard Industrial Classification (KSIC) and Enforcement Rules of KOSPI Market Listing Regulations
- Regulatory Basis: Article 132 of Enforcement Rules of KOSPI Market Listing Regulations
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Industry Reclassification Under Revised Standards
This announcement is a market notice regarding an administrative reclassification of the company’s sub-industry code driven by statutory revisions to standard industrial codes. As this represents an administrative alignment rather than an operational shift in business activities, confirming that there are no underlying changes to Celltrion’s core business model or main revenue drivers is key. Detailed updates can be verified in upcoming periodic reports (Quarterly, Half-Yearly, or Annual Reports) and subsequent KRX disclosures.
📢 Disclaimer & Source Notice
Source: This content has been newly structured and created based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
